What is the prescribing information for the fixed‑combination topical product containing 0.005% calcipotriene (vitamin D3 analogue) and 0.064% betamethasone dipropionate (potent corticosteroid)?

Prescribing Information for Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Fixed-Combination

The fixed-combination product containing calcipotriene 0.005% and betamethasone dipropionate 0.064% is indicated for the treatment of plaque psoriasis in adults, available in multiple formulations (ointment, gel, foam, cream) with the foam formulation demonstrating superior efficacy compared to ointment. 1

Approved Indications

• Primary indication: Treatment of plaque psoriasis in adults 1
• Scalp psoriasis: Calcipotriene plus betamethasone dipropionate gel is specifically recommended for 4-12 weeks for mild to moderate scalp psoriasis 2
• Safety and effectiveness in dermatoses other than psoriasis have not been established 1

Formulation Details

The product contains:

• Active ingredients: Calcipotriene 50 mcg/g (0.005%) + Betamethasone dipropionate 0.5 mg/g (0.064%) 1
• Available formulations: Ointment, gel (topical suspension), aerosol foam, and cream 3, 4
• Ointment base components: Disodium phosphate dihydrate, edetate disodium, mineral oil, white petrolatum, propylene glycol, dl-alpha-tocopherol, steareth-2, and purified water 1

Dosing and Duration

Treatment protocols vary by formulation and clinical scenario:

• Acute treatment: Once or twice daily application for 4 weeks initially 2
• Long-term use: Can be safely used up to 52 weeks, with 69-74% of patients achieving clear or almost clear status with once or twice daily application 2
• Maintenance therapy: Can be used as long-term maintenance following initial treatment success 5, 6
• Combination with systemic therapy: Can be used as adjunct to systemic/biologic drug treatment 5

Alternative Dosing Regimens

• Weekend-weekday approach: Vitamin D analogues twice daily on weekdays combined with high-potency corticosteroids twice daily on weekends (Strength of Recommendation: B) 2
• Morning-evening split: High-potency corticosteroids in morning, vitamin D analogues in evening (Strength of Recommendation: B) 2

Formulation-Specific Efficacy

The aerosol foam formulation demonstrates superior efficacy compared to ointment: At 4 weeks, 54.6% of foam-treated patients achieved treatment success versus 43.0% with ointment (p=0.025), with significantly better PASI score improvements 3. The foam formulation is the only topical therapy approved for both acute (reactive) and proactive management of psoriasis 7.

Site-Specific Considerations

Scalp Psoriasis

• Use calcipotriene foam or calcipotriene plus betamethasone dipropionate gel for 4-12 weeks (Strength of Recommendation: A) 2

Facial Psoriasis

• Consider calcipotriene combined with hydrocortisone for 8 weeks (Strength of Recommendation: B) 2
• Caution: The combination product contains a potent corticosteroid; facial use requires careful monitoring

High-Impact Areas

• Can be used on scalp, peripheral facial areas, skin folds, and palmoplantar areas with treatment schedules varying by severity 5

Safety Profile and Adverse Events

Long-term safety data (up to 52 weeks) demonstrates excellent tolerability:

• No serious adverse events including striae or hypothalamic-pituitary-adrenal (HPA) axis suppression observed over 52 weeks 2
• Most adverse events are mild to moderate in severity 8
• Most common treatment-related adverse events are application-site reactions 8
• One adverse drug reaction reported with foam: application site itch 3
• No clinically relevant effects on calcium homeostasis or HPA axis 8

Age-Related Considerations

• Geriatric patients: Analysis showed statistically significant difference in severity of skin-related adverse events (more severe in patients >65 years versus <65 years) 1
• Pediatric patients: Safety and effectiveness have not been established; pediatric patients are at greater risk of systemic adverse effects due to higher skin surface area to body mass ratio 1

Critical Drug Interactions and Contraindications

Avoid Concurrent Use With:

• Salicylic acid: The acidic pH inactivates calcipotriene and reduces effectiveness 2
• Excessive sun exposure: Calcipotriene may enhance UVR effects on skin tumor formation in animal studies; patients should avoid excessive natural or artificial sunlight exposure 1

Phototherapy Considerations

• Apply AFTER phototherapy: UVA radiation decreases calcipotriene concentration on skin; thick calcipotriene layers can block UVB radiation 2
• Physicians may wish to avoid phototherapy in patients using calcipotriene 1

Special Populations

Pregnancy

• Category C: Use only if potential benefit justifies potential risk to fetus 1
• Animal studies showed skeletal abnormalities at doses near human exposure levels 1

Nursing Mothers

• Unknown if excreted in human milk; exercise caution when administering to nursing women 1

Patient Adherence and Satisfaction

The cream and foam formulations demonstrate high patient satisfaction and adherence:

• Cal/BD cream shows very high satisfaction scores on PTCS and TTAQ questionnaires 9
• 80% of patients (24/30) preferred cream over foam formulation in one study 9
• Favorable cosmetic characteristics contribute to treatment success by enhancing adherence 5

Clinical Pearls

• Efficacy timeline: Vitamin D analogue efficacy noted at 8 weeks but not at 4 weeks; set appropriate patient expectations 2
• Combination therapy: Slightly more efficacious than betamethasone monotherapy 2
• Maintenance strategy: Following initial 4-week treatment, patients can transition to calcipotriene maintenance therapy to retain benefits 6
• Long-term use: Fewer than 5% of patients experienced adverse events associated with long-term corticosteroid use over 1 year 6